Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

Figures & data

Figure 1 Structure of the budget impact model.

Note: ^aOther ART 1: 100% TDF/FTC/c/EVG. ^bOther ART 2: 28.6% TDF/FTC+RAL; 14.3% ABC/3TC/DTG; 14.3% TDF/FTC/c/EVG; 14.3% 3TC/DTG; 14.3% ABC/3TC/NVP; 14.3% ABC/3TC/DRV+r. ^cOther ART 3: 25% TDF/FTC/RPV; 25% ABC/3TC/DRV+r; 50% DRV+r.
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; ATV, atazanavir; c, cobicistat; DRV, darunavir; DTG, dolutegravir; EVG, elvitegravir; FTC, emtricitabine; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; r, ritonavir; RAL, Raltegravir; RPV, rilpivirine; TDF, tenofovir.

Table 1 Results of the budget impact analysis

Scenario	Annual cost (million €)
	Year 1	Year 2	Year 3	Year 4	Year 5	Total
Base case	16.1	16.3	16.4	16.5	16.6	82.0
Scenario 1	12.6	11.2	10.7	10.6	10.6	55.6
Difference between scenario 1 and base case (% impact)	−3.6 (−22.1%)	−5.1 (−31.5%)	−5.7 (−35.0%)	−5.9 (−35.9%)	−5.9 (−35.9%)	−26.3 (−32.1%)
Scenario 2	13.8	12.5	11.8	11.4	11.3	60.8
Difference between scenario 2 and base case (% impact)	−2.4 (−14.7%)	−3.8 (−23.3%)	−4.6 (−28.0%)	−5.0 (−30.6%)	−5.3 (−32.0%)	−21.1 (−25.8%)
Scenario 3	14.7	13.9	13.4	13.0	12.7	67.7
Difference between scenario 3 and base case (% impact)	−1.4 (−8.8%)	−2.4 (−14.8%)	−3.1 (−18.6%)	−3.5 (−21.3%)	−3.8 (−23.2%)	−14.2 (−17.4%)